Balleroni, the US market is small compared to the
Post# of 36536
(Total Views: 331)
Posted On: 02/09/2021 10:36:16 AM
Balleroni, the US market is small compared to the SE Asia, China, halal market. If GNBT gets a foothold there, whether it's sold in the US is irrelevant.
Additionally, the technology to create a vaccine in the manner GNBT has is far more important than even the covid vaccine. It may not seem that way right now, but if the methodology works, and GNBT can manufacture vast quantities on short notice using some ex-vivo testing and computer algorithms, the next time (and there will be one) this happens, who's at the forefront? And of course, that ignores that potential use for the GNBT vaccine development process for existing viruses.
Finally, the PFE and Mod vaccines still have the issue of 1791 free radical antibodies that no one as yet understand how they may or may not affect a vaccine patient long term. If the GNBT vaccine is shown to only target the covid proteins, that again makes the GNBT vaccine far superior from a safety standpoint, and that will allow the entrance to the US market, with or without long term memory.
JMO. The market will sort this all out eventually, and maybe it won't be favorable to GNBT. Remember, everyone said Beta was technically superior to VHS videotapes, but VHS dominated the market and the Betamax was left as a footnote in history. It's possible GNBT will be as well, so it's great that they still have the AE37 drug, the MSO, Altucell, Excellegan, etc to fall back onto.
Additionally, the technology to create a vaccine in the manner GNBT has is far more important than even the covid vaccine. It may not seem that way right now, but if the methodology works, and GNBT can manufacture vast quantities on short notice using some ex-vivo testing and computer algorithms, the next time (and there will be one) this happens, who's at the forefront? And of course, that ignores that potential use for the GNBT vaccine development process for existing viruses.
Finally, the PFE and Mod vaccines still have the issue of 1791 free radical antibodies that no one as yet understand how they may or may not affect a vaccine patient long term. If the GNBT vaccine is shown to only target the covid proteins, that again makes the GNBT vaccine far superior from a safety standpoint, and that will allow the entrance to the US market, with or without long term memory.
JMO. The market will sort this all out eventually, and maybe it won't be favorable to GNBT. Remember, everyone said Beta was technically superior to VHS videotapes, but VHS dominated the market and the Betamax was left as a footnote in history. It's possible GNBT will be as well, so it's great that they still have the AE37 drug, the MSO, Altucell, Excellegan, etc to fall back onto.
(4)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼